PAPablo Juan Alvarez

Pablo Juan Alvarez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Pablo Juan Alvarez has a total of 109 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Methodological proposal to explore and design future health innovation policies and opportunities for Responsible Research and Innovation (RRI)

    by Arturo Argüello, Alicia Ortega-Rodriguez, Pablo Álvarez

    Responsible Research and Innovation (RRI) seeks to align the research results with the needs of society to respond to current and future problems, also encompassing financial instruments, innovative public policies, and the distribution of resources. These policies should prioritize research in those areas with the greatest impact on society, and particularly in health research, this impact should be focused on responding to clinical problems of the population rather than economic impact. A methodology is proposed that uses information from open sources to identify discrepancies between the results of the most translational research of a region and its health needs, in order to provide useful information for the formulation of innovation policies.

  • An updated review of adipose derived-mesenchymal stem cells and their applications in musculoskeletal disorders

    by Mario Rivera-Izquierdo, Laura Cabeza, Antonio Láinez-Ramos-Bossini, Raul Quesada, Gloria Perazzoli, Pablo Alvarez, Jose Prados, Consolación Melguizo

    Introduction: Adipose-derived mesenchymal stem cells (ASCs) represent a new therapeutic strategy in biomedicine with many potential applications, especially in musculoskeletal disorders. Preclinical and clinical studies based on the administration of ASCs support their efficacy in bone regeneration, joint repair, tendon injury and skeletal muscle alterations. Many of these novel treatments may improve patients’ quality of life and prognosis. However, several concerns about the use of stem cells remain unsolved, particularly regarding their safety and side effects. The present work aims to review the nature, clinical trials and patents involving the use of ASCs in musculoskeletal disorders. Area covered: In this article, we describe ASCs’ isolation, culture and differentiation in vivo and in vitro, advances on ASCs’ applications in bone, cartilage, muscle and tendon repair, and patents involving the use of ASCs. Expert opinion: The use of ASCs in musculoskeletal disorders presents significant therapeutic advantages, including limited autoimmune response, potential cell expansion ex vivo, high plasticity to differentiate into several mesodermal cell lineages, and additional effects of therapeutic interest such as secretion of neurotrophic factors and anti-inflammatory properties. For these reasons, ASCs are promising therapeutic agents for clinical applications in musculoskeletal disorders.


  • Latest in Vitro and in Vivo Assay, Clinical Trials and Patents in Cancer Treatment using Curcumin: A Literature Review

    by Kevin Doello, Raúl Ortiz, Pablo J. Alvarez, Consolación Melguizo, Laura Cabeza, José Prados

    Curcumin, the main active compound of the curcuma root, shows antioxidant, anti-inflammatory, and antitumor properties which have been demonstrated in preclinical and clinical trials. Its antitumor activity is mediated by its ability to act directly on the tumor cell, activating apoptosis pathways and indirectly inhibiting the process of inflammation, angiogenesis, and metastasis in the tumor microenvironment. In addition, it has a preventive activity such as radio and/or chemosensitizer. These effects have been evident in in vitro assays but have also been corroborated in patient trials either through the isolated use of curcumin or through its association with other agents. Moreover, curcumin has demonstrated a low induction of side effects. Numerous patents have been developed in connection with the administration and use of curcumin against different types of cancer. All this justifies the interest for the development of new laboratory studies and especially of clinical trials to validate this compound as a dietary supplement in both the healthy and the oncological population. The present review aims to address the most recent in vitro investigations and the latest clinical trials and patents related to the curcumin agent to provide an up-to-date overview of the latest advances in relation to its antitumor effect.


  • Meroxest improves the prognosis of immunocompetent C57BL/6 mice with allografts of E0771 mouse breast tumor cells

    by Esther Carrasco, Jose Manuel Garrido, Pablo Juan Álvarez, Enrique Álvarez-Manzaneda, Rachid Chahboun, Ibtissam Messouri, Consolación Melguizo, Antonia Aránega, Fernando Rodríguez-Serrano

    Introduction : Recently, we have reported the antitumor properties of a new family of synthetic merosesquiterpenes, among which meroxest is highlighted, since it has high activity and specificity for ER+ breast cancer cells. In this paper, we characterize allografts of ER+ E0771 mouse breast...


  • Open Access

    Antioxidant Intake and Antitumor Therapy: Toward Nutritional Recommendations for Optimal Results

    by Nuria Mut-Salud, Pablo Juan Álvarez, Jose Manuel Garrido, Esther Carrasco, Antonia Aránega, Fernando Rodríguez-Serrano

    The role of the induction of oxidative stress as the mechanism of action of many antitumor drugs is acquiring an increasing interest. In such cases, the antitumor therapy success may be conditioned by the antioxidants present in our own body, which can be synthesized de novo (endogenous) or incorporated through the diet and nutritional supplements (exogenous). In this paper, we have reviewed different aspects of antioxidants, including their classification, natural sources, importance in diet, consumption of nutritional supplements, and the impact of antioxidants on health. Moreover, we have focused especially on the study of the interaction between antioxidants and antitumor therapy, considering both radiotherapy and chemotherapy. In this regard, we found that the convenience of administration of antioxidants during cancer treatment still remains a very controversial issue. In general terms, antioxidants could promote or suppress the effectiveness of antitumor treatment and even protect healthy tissues against damage induced by oxidative stress. The effects may depend on many factors discussed in the paper. These factors should be taken into consideration in order to achieve precise nutritional recommendations for patients. The evidence at the moment suggests that the supplementation or restriction of exogenous antioxidants during cancer treatment, as appropriate, could contribute to improving its efficiency.


  • Cancer Stem-Cells Patents in the Context of their Therapeutic Purposes: Exploring the Latest Trends (2011-2015)

    by Pablo Alvarez, Arturo Arguello, Amelia E. Aranega, Celia Velez, Antonia Aranega, Carlos Gonzalez, Jose C. Prados-Salazar

    Abstract: Cancer stem cells (CSCs) are believed to cause cancer recurrence because they resist conventional therapies and restart the growth of tumor cells. CSCs has a specific biological behavior, mainly due to a deregulation of the self-renewal capacity. These cells differ in division and the cell cycle, replication capacity in DNA repair, and deregulation of signaling pathways. Collectively, these results give CSC a malignant phenotype. This review focuses on CSCs oncology patents in the years 2011-2015. Because many inventions have recently been registered in relation to stem cells, our attention focuses on cancer-utility CSCs patents. The patents selected have been analyzed based on their therapeutic usefulness in the area of cancer, and we have detected a clear increase in interest, so that the data of patent applications filed in 2014 is highly significant. Compared with the total for 2013, patents have multiplied by 8.01. On the other hand, 59.57% of all selected patents were useful in oncology in general, opening new therapeutic perspectives for identifying CSCs. We also analyzed the interests of different countries in advancing knowledge in the area of the CSCs as a therapeutic tool for tumors. Some 38% of these patents are registered in the EU, while other countries showed fewer patents in this field of pathologies.

  • Open Access

    Poly(butylcyanoacrylate) and Poly(ε-caprolactone) Nanoparticles Loaded with 5-Fluorouracil Increase the Cytotoxic Effect of the Drug in Experimental Colon Cancer

    by Raúl Ortiz, Laura Cabeza, José L. Arias, Consolación Melguizo, Pablo J. Álvarez, Celia Vélez, Beatriz Clares, Antonia Áranega, Jose Prados

    The clinical use of 5-fluorouracil, one of the drugs of choice in colon cancer therapy, is limited by a nonuniform oral absorption, a short plasma half-life, and by the development of drug resistances by malignant cells. We hypothesized that the formulation of biodegradable nanocarriers for the efficient delivery of this antitumor drug may improve its therapeutic effect against advanced or recurrent colon cancer. Hence, we have engineered two 5-fluorouracil-loaded nanoparticulate systems based on the biodegradable polymers poly(butylcyanoacrylate) and poly(ε-caprolactone). Drug incorporation to the nanosystems was accomplished by entrapment (encapsulation/dispersion) within the polymeric network during nanoparticle synthesis, i.e., by anionic polymerization of the monomer and interfacial polymer disposition, respectively. Main factors determining 5-fluorouracil incorporation within the polymeric nanomatrices were investigated. These nanocarriers were characterized by high drug entrapment efficiencies and sustained drug-release profiles. In vitro studies using human and murine colon cancer cell lines demonstrated that both types of nanocarriers significantly increased the antiproliferative effect of the encapsulated drug. In addition, both nanoformulations produced in vivo an intense tumor growth inhibition and increased the mice survival rate, being the greater tumor volume reduction obtained when using the poly(ε-caprolactone)-based formulation. These results suggest that these nanocarriers may improve the antitumor activity of 5-fluorouracil and could be used against advanced or recurrent colon cancer.


  • Transcriptional Profiling of Peripheral Blood in Pancreatic Adenocarcinoma Patients Identifies Diagnostic Biomarkers

    by Octavio Caba, Jose Prados, Raúl Ortiz, Cristina Jiménez-Luna, Consolación Melguizo, Pablo J. Álvarez, Juan R. Delgado, Antonio Irigoyen, Ignacio Rojas, Javier Pérez-Florido, et al.

    Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy associated with poor survival rates. Fast detection of PDAC appears to be the most relevant strategy to improve the long-term survival of patients. Our objective was to identify new markers in peripheral blood that differentiates between PDAC patients and healthy controls. Peripheral blood samples from PDAC patients (n = 18) and controls (n = 18) were analyzed by whole genome cDNA microarray hybridization. The most relevant genes were validated by quantitative real-time PCR (RT-qPCR) in the same set of samples. Finally, our gene prediction set was tested in a blinded set of new peripheral blood samples (n = 30). Microarray studies identified 87 genes differentially expressed in peripheral blood samples from PDAC patients. Four of these genes were selected for analysis by RT-qPCR, which confirmed the previously observed changes. In our blinded validation study, the combination of CLEC4D and IRAK3 predicted the diagnosis of PDAC with 93 % accuracy, with a sensitivity of 86 % and specificity of 100 %. Peripheral blood gene expression profiling is an useful tool for the diagnosis of PDAC. We present a validated four-gene predictor set (ANKRD22, CLEC4D, VNN1, and IRAK3) that may be useful in PDAC diagnosis.


  • Open Access

    Prognostic impact of MGMT promoter methylation and MGMT and CD133 expression in colorectal adenocarcinoma

    by Jaime Antonio Oliver, Raúl Ortiz, Consolación Melguizo, Pablo Juan Álvarez, Jaime Gómez-Millán, Jose Prados

    New biomarkers are needed for the prognosis of advanced colorectal cancer, which remains incurable by conventional treatments. O6-methylguanine DNA methyltransferase (MGMT) methylation and protein expression have been related to colorectal cancer treatment failure and tumor progression. Moreover, the presence in these tumors of cancer stem cells, which are characterized by CD133 expression, has been associated with chemoresistance, radioresistance, metastasis, and local recurrence. The objective of this study was to determine the prognostic value of CD133 and MGMT and their possible interaction in colorectal cancer patients.


  • ABC transporters as differentiation markers in glioblastoma cells

    by Ana R. Rama, Pablo J. Alvarez, Roberto Madeddu, Antonia Aranega

    Glioblastoma multiforme (GBM) is the most common primary malignant brain tumour, characterized by a high aggressivity, a huge heterogeneity attending a hierarchical model and resistance to therapy. Drug resistance has been correlated with the presence of the ABC efflux transporters which are able to exclude drugs for the cellular cytoplasm. In the nucleus of the GBM, initiating cells (ICs) can self-renew and give rise to cancer stem cells, which differ to the side population cells and the different cellular subtypes that form the mass around them. The ICs do not express or express ATP binding cassette (ABC) at very low levels, but this expression may increase with the differentiation process. We suggest that the differentiation process may be responsible of chemoresistance of the GBM cells. We compared three ABC transporters expression: ABCA1, MRP4 and MRP5, in the ICs obtained from 9 patients with GBM and their respective differentiated GBM cells. We show an overexpression of the three ABC transporters in the differentiated GBM cells in comparison to ICs. Implications of the hypothesis: The blockade of these ABC transporters could help to improve the drug effectivity and thus reduce the tumour growth and prevent the tumour recurrence.